RAPID ACCESS TO INTERVENTION DEVELOPMENT - ADDENDUM Release Date: June 16, 1999 P.T. National Cancer Institute In the May 11,1998 issue of the NIH Guide for Grants and Contracts, the National Cancer Institute (NCI) announced a new initiative: Rapid Access to Intervention Development (RAID). The purpose of this Notice is to announce two changes to the RAID program, effective immediately: 1) requests to produce materials ready for use in clinical trials must have a letter of commitment to actually conduct the trial from an Institution where the clinical trial would occur; and, 2) if the receipt dates, February 1 and August 1 of each year, fall on a weekend or holiday, the receipt date will be the following business day. A previous addendum in the December 18,1998 issue of the NIH Guide for Grants and Contracts clarified that 1) academic investigators now may have collaborations with small business partners and still qualify for RAID funding; and, 2) a maximum of two distinct requests for support per investigator can be submitted per receipt date. The following is a brief overview of the RAID program, with a link to the RAID web site. RAID will make available to academic investigators the preclinical development contract resources of NCI's Developmental Therapeutics Program. The goal of RAID is the rapid movement of novel molecules and concepts from the laboratory to the clinic for proof-of-principle clinical trials. RAID will assist investigators who submit successful requests by providing any (or all) of the pre-clinical developmental requirements for clinical translation. These include, for example, production, bulk supply, good manufacturing practices (GMP) standards, formulation, and toxicology. Suitable types of agents for RAID include small molecules, biologics, or vaccines. For more information, visit the web site, http://dtp.nci.nih.gov/. Requests for RAID resources are to be submitted as described in the web site. Written requests will be evaluated by a specially constituted RAID panel consisting of selected NCI staff (non voting) and outside experts from academia and industry. All requests for support must be submitted directly to the office listed below under INQUIRIES. INQUIRIES Inquiries are encouraged, and the opportunity to clarify issues or questions is welcome. Inquiries may be directed to: RAID, Office of Associate Director Developmental Therapeutics Program National Cancer Institute 6130 Executive Boulevard, Suite 843 Bethesda, MD 20892 Rockville, MD 20852 (for express/courier service) Telephone: (301) 496-8720 FAX: (301) 402-0831 Email: sausville@dtpax2.ncifcrf.gov
Return to NIH Guide Main Index
Office of Extramural Research (OER) |
National Institutes of Health (NIH) 9000 Rockville Pike Bethesda, Maryland 20892 |
Department of Health and Human Services (HHS) |
||||||||
Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, RealPlayer, Video or Flash files, see Help Downloading Files. |